This week's Houston innovators to know includes Juliana Garaizar of Greentown Labs, Derek Armstrong of Armstrong Innovations, and Megan Siliainoff of Med Meg Creative Services. Courtesy photos

It's a new month and Houston's innovation ecosystem is continuing to grow amid the coronavirus pandemic. This week's Houston innovators to know roundup reflects that growth with a new-to-town incubator's newly names leader — plus an entrepreneur creating an virtual reality app to escape and a communications expert's advice on navigating COVID-19.

Juliana Garaizar, launch director of Greentown Houston

Juliana Garaizar is working to help set up Houston's Greentown Labs incubator with diversity and inclusion in mind. Courtesy photo

Juliana Garaizar has had to keep a huge secret for a while. The launch director of new-to-Houston Greentown Labs has known about the cleantech incubator's plan to expand to the Bayou City for a while, and now the news is out. Of course, launching amid a pandemic isn't ideal, but Garaizar says its allowed a strong relationship with the original group based in Boston to form.

"I think the silver lining of this COVID-19 experience is that we are much more integrated with the Boston team, and we're learning at a much faster rate," she says. "That's why we decided to also open Houston for virtual memberships before we open our building in Q1 of 2021."

Garaizar joined the Houston Innovators Podcast last week to share her experience with the organization and how she'll be setting up Houston operations with diversity and inclusion in mind. Read more and stream the episode.

Derek Armstrong, CEO and founder of Armstrong Innovations

Derek Armstrong, a Houston native, founded his design company, Armstrong Innovations. Photo courtesy of Oculus Go

Derek Armstrong had been working on a new virtual reality app for relaxation and meditation that users can enter into for an opportunity to escape reality for a bit — little did he know that was something more people than ever would want to do.

His company, a Houston-area industrial design startup, Armstrong Innovations, just launched two Oculus Go app games, aptly named 'Escape'. The VR app was designed with relaxation and meditation in mind but has doubled as a new way to relax and sightsee without leaving your home during the COVID-19 pandemic.

"The sights and sounds of our new app assist with mindfulness and meditation," says CEO and founder Derek Armstrong. "It's about focusing on the sights and sounds, especially with the virus growing. It's a quick getaway without having to physically go anywhere." Read more.

Megan Silianoff, founder and creative director of Mad Meg Creative Services

Megan Silianoff has been helping clients navigate communications during a pandemic. Courtesy photo

The worst part of contracting COVID-19 — aside from suffering from the disease itself — is diligently communicating the risk of exposure to people you've been around especially to coworkers, employees, clients, etc. In a guest article for InnovationMap, Megan Silianoff of Mad Meg Creative Services, sets the scene for you to be prepared should you find yourself in this situation,

"We understand as communication experts, informing a client, boss, or anyone that you've potentially exposed them is scary messaging to share," she writes. "Guilt is the number one emotion people report experiencing when they realize they've potentially exposed someone or a group of people, even though the respective exposure was inadvertent. Nevertheless it's crucial to communicate the exposure quickly and effectively as that's how Houston can hinder the spread of this disease through our city." Read more.

Oculus Go is enabling users to their canceled travels with a virtual getaway. Image courtesy of Oculus Go

Virtual reality app developed in Houston allows users to escape to far away lands

there's an app for that

While rising coronavirus cases in the area have canceled so many summer vacations, not all hope of sightseeing this summer is lost. A Houston entrepreneur has created a virtual alternative.

Houston-area industrial design startup, Armstrong Innovations launched two Oculus Go app games, aptly named 'Escape'. The VR app was designed with relaxation and meditation in mind but has doubled as a new way to relax and sightsee without leaving your home during the COVID-19 pandemic.

"The sights and sounds of our new app assist with mindfulness and meditation," says CEO and founder Derek Armstrong. "It's about focusing on the sights and sounds, especially with the virus growing. It's a quick getaway without having to physically go anywhere."

The project began a year ago and was completed in March — right at the start of stay-at-home orders that paralyzed everyday life before launching this month. The company's new array of Occulus Go experiences aims at easing the mind and spirits, but with the rise of coronavirus 'Escape' can also serve to calm frayed nerves.

The app is based on popular view master toys and stereoscopes from the 1800s that are reminiscent of exploration tools used over the years. There are two different experiences to choose from one named 'Escape: Roma' for its old-world inspired poolside lounge and another named 'Escape: Utopia', which brings outer space to life in front of an Oculus user's eyes.

"The app has already gotten a lot of traction in places where people are not able to go out in the world," says Armstrong. "It's so easy just to pop on your Oculus headset, open the app, and zone out or relax for a few minutes."

The local industrial design startup was founded in 2018, and it has already released a few music packs with tracks ranging from horror titles to 8-bit retro remakes for Unreal Engine projects, an advanced real-time 3D creation tool that serves as a game engine for creators to deliver interactive experiences. The music packs are a collection of audio assets made in collaboration with Epic Games.

"Our company is focused on creating engaging gamified experiences," says Armstrong. "The inspiration for our packs and now our new app came from my interest in treating PTSD and how virtual reality can help ease the symptoms of anxiety in some cases."

Armstrong, a Houston native, describes himself as a "maker of stuff," with previous experience in music production and a passion for design. According to him, his hometown is the best place to be.

"Houston really has everything you need, when it comes to new innovations and technology," says Armstrong. "I would prefer to have my business rooted in Houston rather than moving to a design startup hotspot."

Armstrong Innovations hopes to grow into new areas of the industrial design world, especially in military-driven technologies and other video game opportunities in the next year or so. Product keys for 'Escape' can be purchased online now, available worldwide for maximum relaxation.


Derek Armstrong, a Houston native, founded his design company, Armstrong Innovations. Photo courtesy of Oculus Go

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.